At this year’s International Society of Cell and Gene Therapy 30th Annual Conference in Vancounver, Canada, Ori Biotech Ltd. (Ori) announced the commercial launch of IRO®, a next-generation platform built specifically to overcome the current challenges in CGT manufacturing.
In a plenary presentation, Ori Biotech CEO Jason C. Foster revealed the IRO platform to a packed audience, hosted by Ori Biotech Chair Bruce Levine.
Following the announcement, CTMC CEO Jason Bock shared data from the organisation’s first trials of IRO within their cell therapy development process.
Manufacturing remains a critical barrier to scaling cell and gene therapies, limiting the clinical and commercial impact of this life-saving new class of therapies. It is estimated that more than 95% of patients are left without access to cell and gene therapies. Ori has developed the IRO platform as part of their mission to enable widespread patient access to life-saving cell and gene therapies.
Find all the materials from the event below.
